ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "autoantibodies"

  • Abstract Number: 282 • 2016 ACR/ARHP Annual Meeting

    From ‘immune Mediated Necrotizing Myopathy’ to ‘antibody-Mediated Necrotizing Myositis: Towards the Pathogenic Role of Anti-SRP and Anti-Hmgcr Antibodies’

    Yves Allenbach1, Louiza Arouche-Delaperche2, Corinna Preusse3, Gillian Butler Browne2, Nicolas Champtiaux4, Kuberaka Mariampillai5, Aude Rigolet6, Peter Hufnagl7, Norman Zerbe8, Thierry Maisonobe9, Damien Amelin2, Sarah Leonard-louis10, Charles Duyckaerts11, Bruno Eymard12, Hans-Hilmar Goebel3, Laurent Drouot13, Olivier Boyer14, Olivier Benveniste2,5 and Werner Stenzel3, 1Pitié-Salpêtrière University Hospital, AP-HP, Department of Internal Medicine and Clinical Immunology, Paris, France, Paris, France, 2Sorbonne Universités UPMC Univ Paris 06, Myology research center, INSERM UMRS974, CNRS FRE3617, Pitié-Salpêtrière University Hospital, Paris, France, Paris, France, 3Charité - Universitätsmedizin, Department of Neuropathology, Berlin, Germany, Berlin, Germany, 4Department de Internal Medicine and Clinical Immunology, Hôpital Pitié-Salpêtrière, AP-PH, UPMC, Paris, France, 5Assistance Publique - Hôpitaux de Paris, Pitié-Salpêtrière University Hospital, Department of Internal Medicine and Clinical Immunology, Hospital University Department: inflammation, immunopathology and biotherapy (DHU i2B), Paris, France, Paris, France, 6Internal Medicine, Pitié-Salpêtrière University Hospital, Paris, France, 7Pathology departmen, Charite Hospital, Berlin, Germany, 8Department of Pathology, Charite Hospital, Berlin, Germany, 9Pitié-Salpêtrière University Hospital, AP-HP, Department of Neuropathology, Paris, France, Paris, France, 10Assistance Publique - Hôpitaux de Paris, Pitié-Salpêtrière University Hospital, Department of Neuropathology, Paris, France, Paris, France, 11Neuropathology, Pitie-Salpetriere Hospital, Paris, France, 12Department of Neurology, Hôpital Pitié-Salpêtrière, AP-PH, UPMC, Paris, France, 13Immunology, INSERM U905, University of Rouen, Rouen, France, 14Immunology, Inserm 905 & Institute for Biomedical Research, University of Rouen, Rouen, France

    Background/Purpose: Immune mediated necrotizing myopathy (IMNM) has been recently added as a new entity among dermatomyositis, polymyositis and sporadic inclusion body myositis. IMNM is defined…
  • Abstract Number: 1083 • 2016 ACR/ARHP Annual Meeting

    Discovery and Subsequent Diagnostic Verification of Autoantibodies Against the Major Vault Protein (MVP) in Systemic Lupus Erythematosus

    Petra Budde1, Johannes Schulte-Pelkum1, Daniel Wirtz1, Hans-Dieter Zucht1, Heike Göhler1, Stefan Vordenbäumen2, Peter Schulz-Knappe1 and Matthias Schneider3, 1Protagen AG, Dortmund, Germany, 2Rheumatology, Heinrich-Heine-University Düsseldorf, Düsseldorf, Germany, 3Rheumatology, Heinrich-Heine-University, Duesseldorf, Germany

    Background/Purpose: In systemic lupus erythematosus (SLE), early diagnosis and prognostic stratification are still great challenges. The broad characterization of the autoantibody repertoire in SLE is…
  • Abstract Number: 2318 • 2016 ACR/ARHP Annual Meeting

    Real World Use of the Myositis Autoantibody Panel

    Jason Weiner1, Ryan Jessee2, Robert T. Keenan3, Michael Datto4 and Lisa Criscione-Schreiber5, 1Division of Rheumatology, Duke University, Durham, NC, 2Division of Internal Medicine, Duke University, Durham, NC, 3Rheumatology, Duke University, Durham, NC, 4Division of Pathology, Duke University, Durham, NC, 5Division of Rheumatology, Department of Medicine, Duke University, Durham, NC

    Background/Purpose: The identification of myositis specific and associated autoantibodies occurring in idiopathic inflammatory myopathies (IIMs) has improved classification and prognosis determinations.   With commercial availability, these…
  • Abstract Number: 285 • 2016 ACR/ARHP Annual Meeting

    Antibodies to Small Ubiquitin-like Modifier Activating Enzyme: Frequency and Characteristics of Antibody-Positive Patients in an Unselected Cohort

    Anne Tebo1, Troy Jaskowski2 and Lisa Peterson1, 1Pathology, University of Utah School of Medicine and ARUP Laboratories, Salt Lake City, UT, 2ARUP Laboratories, Salt Lake City, UT

    Background/Purpose:  Antibodies to small ubiquitin-like modifier activating enzyme (SAE) are associated with diagnosis of dermatomyositis (DM). The aims of this study were to establish the…
  • Abstract Number: 1112 • 2016 ACR/ARHP Annual Meeting

    Hypoxia Modulates Neutrophil Integrin Expression, Adhesion and Trans-Endothelial Migration

    Akif A. Khawaja1,2, Charis Pericleous3,4, Vera M. Ripoll1, Joanna C. Porter5 and Ian Giles3, 1Centre for Rheumatology, Division of Medicine, Centre for Rheumatology, University College London, London, United Kingdom, 2Centre for Inflammation and Tissue Repair, Centre for Inflammation and Tissue Repair, University College London, London, United Kingdom, 3Centre for Rheumatology, University College London, Centre for Rheumatology, University College London, London, United Kingdom, 4Imperial College Vascular Sciences, National Heart and Lung Institute, Imperial College Vascular Sciences, National Heart and Lung Institute, London, United Kingdom, 5Centre for Inflammation and Tissue Repair, Division of Medicine, Centre for Inflammation and Tissue Repair, University College London, London, United Kingdom

    Background/Purpose: Dysregulation of neutrophil activation is important in the pathogenesis of various inflammatory and autoimmune rheumatic diseases (ARDs), including RA, SLE and APS. Neutrophils are…
  • Abstract Number: 2423 • 2016 ACR/ARHP Annual Meeting

    Differential Interferon Score Expression in the Peripheral Blood in Mendelian Inflammatory Interferonopathies Versus Juvenile Dermatomyositis (JDM) Subtyped By Myositis Autoantibodies and Disease Activity

    Hanna Kim1, Terrance P. O'Hanlon2, Adriana Almeida de Jesus3, Yan Huang3, Ira N. Targoff4,5, Frederick W. Miller2, Raphaela Goldbach-Mansky6 and Lisa G. Rider2, 1NIAMS/NIH, Bethesda, MD, 2Environmental Autoimmunity Group, NIEHS, NIH, Bethesda, MD, 3National Institute of Allergy and Infectious Diseases (NIAID), NIH, Bethesda, MD, 4Oklahoma Medical Research Foundation, Oklahoma City, OK, 5University of Oklahoma, Oklahoma City, OK, 6Translational Autoinflammatory Disease Studies, National Institute of Allergy and Infectious Diseases (NIAID), NIH, Bethesda, MD

    Background/Purpose: JDM is a complex autoimmune disease with an interferon (IFN) signature, with a reported correlation with disease activity.  Clinical features vary among myositis-specific autoantibody…
  • Abstract Number: 467 • 2016 ACR/ARHP Annual Meeting

    Interleukin-21-Signaling in B Cells, but Not in T Cells, Is Indispensable for Development of Collagen-Induced Arthritis in Mice

    Koji Sakuraba1,2, Kenjiro Fujimura1,2, Hisaaki Miyahara1 and Hisakata Yamada2, 1Clinical Research Center, National Hospital Organization Kyushu Medical Center, Fukuoka, Japan, 2Division of Host Defense, Medical Institute of Bioregulation, Kyushu University, Fukuoka, Japan

    Background/Purpose:  IL-21 is a T cell-derived cytokine whose receptor is expressed on variety of cells in immune system. IL-21was reported to be involved in the…
  • Abstract Number: 1208 • 2016 ACR/ARHP Annual Meeting

    High-Throughput Screening Discovers Multiple Novel Autoantibodies in Rheumatoid Arthritis, Systemic Lupus, Systemic Sclerosis and Sjogrens Syndrome

    Peter Schulz-Knappe1, Hans-Dieter Zucht1, Petra Budde1, Heike Göhler1, Daniel Wirtz1, Johannes Schulte-Pelkum1, Stefan Vordenbäumen2, Torsten Witte3 and Prof. Dr. Matthias Schneider4, 1Protagen AG, Dortmund, Germany, 2Rheumatology, Heinrich-Heine-University Düsseldorf, Düsseldorf, Germany, 3Department of Clinical Immunology and Rheumatology, Hannover Medical School, Hannover, Germany, 4Department of Rheumatology & Hiller Research Unit, Heinrich-Heine University, Düsseldorf, Germany

    Background/Purpose: Diagnostic biomarkers are decision-making tools in clinical lab routine and are of growing importance for clinical management of patients. In autoimmune diseases, one important…
  • Abstract Number: 2424 • 2016 ACR/ARHP Annual Meeting

    Novel Autoantigens for Anti- Endothelial Cell Antibodies in Pediatric Rheumatic Diseases Identified By Proteomics

    Rie Karasawa1, Mayumi Tamaki1, Toshiko Sato1, Kazuo Yudoh2 and James Jarvis3, 1Institute of Medical Science, St. Marianna University School of Medicine, Kawasaki, Japan, 2Institute of Medical Science, St. Marianna University School of Medicine, Kanagawa, Japan, 3Pediatrics, The University at Buffalo, Buffalo, NY

    Background/Purpose:  Juvenile dermatomyositis (JDM), a systemic autoimmune vasculopathy, and juvenile idiopathic arthritis (JIA) are representative rheumatic diseases in children. However the pathogenesis of these diseases…
  • Abstract Number: 493 • 2016 ACR/ARHP Annual Meeting

    The 2010 ACR/EULAR Criteria Are Not Sufficiently Accurate in the Early Identification of Autoantibody-Negative Rheumatoid Arthritis

    Debbie M. Boeters1, Cécile Gaujoux-Viala2, Arnaud Constantin3 and Annette H.M. van der Helm-van Mil1, 1Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, 2Rheumatology Department, University Hospital of Nîmes and EA2415, Montpellier University, Nîmes, France, 3Rheumatology, CHU Purpan - Hôpital Pierre-Paul Riquet, Toulouse, France

    Background/Purpose:  The 2010-ACR/EULAR criteria were derived to classify RA earlier in time. Previous studies indeed observed that the 2010-criteria were fulfilled earlier than the 1987-criteria.…
  • Abstract Number: 1214 • 2016 ACR/ARHP Annual Meeting

    Autoantibody Reactivities Correlated with SLE Disease Activity Identified By the SLE-key® iCHIP® Platform

    Chaim Putterman1, Pennina Safer2, Keren Jakobi2, Rachel Sorek2, Ilana Gilkaite2, Kyle Ferber3, Steve Wallace3, Amanda Harris Altice3, D. Scott Batty3 and Irun R Cohen2,4, 1Albert Einstein College of Medicine, Bronx, NY, 2ImmunArray LTD, Rehovot, Israel, 3ImmunArray Inc., Richmond, VA, 4Immunology, Weizmann Institute of Science, Rehovot, Israel

    Background/Purpose: We have developed an antigen microarray technology to study antibody profiles to elucidate and diagnose clinical states of SLE patients – the iCHIP® SLE-key®…
  • Abstract Number: 2634 • 2016 ACR/ARHP Annual Meeting

    Lack of Autoantibodies to Peptidyl Arginine Deiminase 4 Predict Increased Efficacy of Mavrilimumab in Rheumatoid Arthritis

    Ethan Grant1, Martin Schwickart2, Alex Godwood3, Rachel Moate3, Esther Song2, Carlos Chavez2, Marius Albulescu4, David Close4, Meina Liang2, Tomas Mustelin5, Zhengbin Yao6 and Koustubh Ranade1, 1Translational Medicine, MedImmune, Gaithersburg, MD, 2Clinical Pharmacology and DMPK, MedImmune, Gaithersburg, MD, 3MedImmune, Cambridge, United Kingdom, 4Clinical Development, MedImmune, Cambridge, United Kingdom, 5Respiratory, Inflammation and Autoimmunity, MedImmune, Gaithersburg, MD, 6Respiratory, Inflammation and Autoimmunity iMED, MedImmune, Gaithersburg, MD

    Background/Purpose:  Mavrilimumab is an anti-GM-CSF receptor Ab that has recently demonstrated clinical efficacy in Phase 2 studies in rheumatoid arthritis (RA) patients. Predictive biomarkers to…
  • Abstract Number: 504 • 2016 ACR/ARHP Annual Meeting

    Clinical Significance of Multiple Autoantibody Specificities in Rheumatoid Arthritis: The Role of Anti-Citrullinated Alpha-Enolase and Anti-Interferon Inducible Protein 16 Antibodies

    Alessia Alunno1, Onelia Bistoni1, Federico Pratesi2, Valeria Caneparo3, Fabiana Topini1, Ilaria Puxeddu2, Marco De Andrea4, Santo Landolfo4, Paola Migliorini2 and Roberto Gerli1, 1Department of Medicine, Rheumatology Unit, University of Perugia, Perugia, Italy, 2Department of Clinical and Experimental Medicine, Clinical Immunology Unit, University of Pisa, Pisa, Italy, 3Department of Translational Medicine, Virology Unit, Novara Medical School, Novara, Italy, 4Department of Public Health and Pediatric Sciences, Viral Pathogenesis Unit, Turin Medical School, Torino, Italy

    Background/Purpose: Anti-cyclic citrullinated peptide (anti-CCP) auto-antibodies (auto-Abs) represent the current gold standard for the diagnosis of rheumatoid arthritis (RA). However, growing evidence suggests that a…
  • Abstract Number: 1562 • 2016 ACR/ARHP Annual Meeting

    Interaction Between Antibodies to Paraoxonase 1 and PON1 rs662 Polymorphism: New Clues to Understand HDL Dysfunction and Oxidative Stress in Rheumatoid Arthritis

    Javier Rodríguez-Carrio1, Mercedes Alperi-López2, Raquel López-Mejías3, Patricia López1, Francisco Javier Ballina-García2, Francisco Abal4, Miguel Angel Gonzalez-Gay3,5 and Ana Suárez1, 1Area of Immunology, Department of Functional Biology, University of Oviedo, Oviedo, Spain, 2Department of Rheumatology, Hospital Universitario Central de Asturias, Asturias, Spain, 3Epidemiology, Genetics and Atherosclerosis Research Group on Systemic Inflammatory Diseases, IDIVAL, Santander, Spain, 4Centro de Salud Sariego, Siero, Servicio de Salud del Principado de Asturias (SESPA), Siero, Spain, 5School of Medicine, University of Cantabria, Santander, Spain

    Background/Purpose: Traditional and non-traditional cardiovascular (CV) risk factors underlie CV disease occurrence in rheumatoid arthritis (RA). Recently, a functional impairment of HDL antioxidant capacity has…
  • Abstract Number: 2662 • 2016 ACR/ARHP Annual Meeting

    Effect of Tobacco Smoking on the Clinical, Histopathological, and Serological Manifestations of SjöGren’s Syndrome

    Astrid Rasmussen1, Donald U. Stone2, Dustin Fife3, Michael Brown4, Keith Earley5, Lida Radfar6, C. Erick Kaufman7, David M. Lewis8, Nelson L. Rhodus9, Barbara M. Segal10, Daniel J Wallace11, Michael Weisman12, Swamy Venuturupalli13, Michael T. Brennan14, Christopher J Lessard3, Courtney G. Montgomery15, R. Hal Scofield15 and Kathy L. Sivils15, 1Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation, USA, Oklahoma City, OK, 2King Khaled Eye Specialist Hospital, Riyadh, Saudi Arabia, 3Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, 4Pfizer Inc., Groton, CT, 559th Medical Wing, US Air Force, San Antonio, TX, 6Oral Diagnosis and Radiology Department, University of Oklahoma College of Dentistry, Oklahoma City, OK, 7Medicine, University of Oklahoam Health Sciences Center, Oklahoma City, OK, 8Department of Oral and Maxillofacial Pathology, University of Oklahoma College of Dentistry, Oklahoma City, OK, 9Department of Diagnostic and Biological Sciences, University of Minnesota School of Dentistry, Minneapolis, MN, 10Division of Rheumatology, University of Minnesota Medical School, Minneapolis, MN, 11Division of Rheumatology, Cedars-Sinai Medical Center, Los Angeles, CA, 12Rheumatology, Cedars-Sinai Medical Center, Los Angeles, CA, 13Division of Rheumatology, Cedars Sinai Medical Center, Los Angeles, CA, 14Department of Oral Medicine, Carolinas Medical Center, Charlotte, NC, 15Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK

    Background/Purpose: To assess the prevalence of smoking in patients with Sjögren’s syndrome (SS) and non-Sjögren’s sicca (non-SS sicca), and the association of smoking habits with…
  • « Previous Page
  • 1
  • …
  • 9
  • 10
  • 11
  • 12
  • 13
  • …
  • 28
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology